NCT01668641CompletedPhase 2
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Galapagos NV
- Enrollment
- 91
- Locations
- 19
- Primary Endpoint
- The number of patients with an ACR20 score at Week 4 as a measure of efficacy
Study Overview
Brief Summary
- Ninety patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 (4 different doses will be evaluated) or matching placebo for 4 weeks.
- During the course of the study, patients will also be examined for any side effects that may occur, and the amount of GLPG0634 present in the blood as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be determined.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;
- •Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study;
- •If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening;
- •If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least 2 weeks prior to screening;
- •Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year;
- •Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug.
- •Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and
- •Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.
Exclusion Criteria
- •Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate;
- •Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);
- •Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening;
- •Previous use of the study drug GLPG0634;
- •Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening;
- •Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator;
- •Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A;
- •History of any inflammatory rheumatological disorders other than RA;
- •History of tuberculosis (TB) infection
Arms & Interventions
capsule, 30mg GLPG0634 once a day
Experimental
3 capsules of 10 mg once a day
Intervention: GLPG0634 (Drug)
capsules, 75mg GLPG0634 once a day
Experimental
3 capsules of 25mg once a day
Intervention: GLPG0634 (Drug)
capsules, 150mg GLPG0634 once a day
Experimental
3 capsules of 50mg once a day
Intervention: GLPG0634 (Drug)
capsules, 300mg GLPG0634 once a day
Experimental
3 capsules of 100mg once a day
Intervention: GLPG0634 (Drug)
capsules, placebo once a day
Placebo Comparator
3 capsules placebo once a day
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
The number of patients with an ACR20 score at Week 4 as a measure of efficacy
Time Frame: Week 4 (end of treatment visit)
To preliminary evaluate the efficacy of GLPG0634 compared to placebo in terms of the proportion of subjects achieving an ACR20 response at Week 4
Secondary Outcomes
- The number of patients with ACR20/50/70 response, time to response and DAS28 score at every visit as a measure of efficacy(From Day -1 up to end of treatment visit (week 4))
- The number of patients with adverse events, abnormal lab tests, vital signs and ECG as a measure of safety and tolerability(From screening up to 10 days after last dose)
- The plasma levels of GLPG0634 as a measure of PK(Week 1, week 2 and week 4 visits)
- The plasma levels of GLPG0634 and MTX as a measure of PK(Day -1 and Week 2 or 4 visit (8 hour-sampling))
- The levels of immune- and inflammation-related parameters in plasma as a measure of PD(Day -1, Week 1, week 2 and week 4 visits)
Investigators
Study Sites (19)
Loading locations...
Similar Trials
Completed
Phase 2
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)Rheumatoid ArthritisNCT01888874Galapagos NV599
Completed
Phase 2
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)Rheumatoid ArthritisNCT01894516Galapagos NV287
Completed
Phase 2
GLPG0259 in Methotrexate-refractory Rheumatoid ArthritisRheumatoid ArthritisNCT01211249Galapagos NV30
Completed
Phase 2
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)Rheumatoid ArthritisNCT01526057Pfizer220
Completed
Phase 3
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00299130Genentech, Inc.511